KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Cost of Revenue (2017 - 2026)

Aquestive Therapeutics has reported Cost of Revenue over the past 9 years, most recently at -$7.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 254.47% year-over-year to -$7.0 million; the TTM value through Dec 2025 reached $5.7 million, down 67.9%, while the annual FY2025 figure was $5.7 million, 67.9% down from the prior year.
  • Cost of Revenue for Q4 2025 was -$7.0 million at Aquestive Therapeutics, down from $4.5 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $6.6 million in Q2 2023 and troughed at -$7.0 million in Q4 2025.
  • A 5-year average of $3.9 million and a median of $4.5 million in 2025 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: surged 57.61% in 2022 and later tumbled 254.47% in 2025.
  • Year by year, Cost of Revenue stood at $3.4 million in 2021, then surged by 57.61% to $5.3 million in 2022, then increased by 3.34% to $5.5 million in 2023, then dropped by 17.55% to $4.5 million in 2024, then tumbled by 254.47% to -$7.0 million in 2025.
  • Business Quant data shows Cost of Revenue for AQST at -$7.0 million in Q4 2025, $4.5 million in Q3 2025, and $4.6 million in Q2 2025.